Literature DB >> 29259851

Fibrodysplasia ossificans progressiva: Basic understanding and experimental models.

Zijuan Qi1,2, Jing Luan2, Xiaoyan Zhou2, Yazhou Cui2, Jinxiang Han2.   

Abstract

Fibrodysplasia ossificans progressive (FOP) is an extremely rare autosomal dominant disorder characterized by congenital malformations of the great toes and progressive heterotopic ossification that can induce a disabling second skeleton. Spontaneously occurring flare-ups can cause inflammatory soft tissue to swell, followed by progressive and disabling heterotopic endochondral ossification. FOP is very rare, with an estimated incidence of one case per two million individuals. There is no definitive treatment for FOP, but the longevity of patients with FOP can be extended by early diagnosis and appropriate prevention of flares-up. Some promising treatment strategies and targets have recently been reported. The current review describes the classical phenotype and genotype of FOP, useful methods of diagnosing the condition, therapeutic approaches and commonly used drugs, and experimental models used to study this disease.

Entities:  

Keywords:  Fibrodysplasia ossificans progressive; disease modeling; induced pluripotent stem cells; phenotype and genotype

Year:  2017        PMID: 29259851      PMCID: PMC5735276          DOI: 10.5582/irdr.2017.01055

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN: 2186-3644


  51 in total

Review 1.  Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition.

Authors:  Daniel L Simmons; Regina M Botting; Timothy Hla
Journal:  Pharmacol Rev       Date:  2004-09       Impact factor: 25.468

Review 2.  Fibrodysplasia ossificans progressiva: why do some people have two skeletons?

Authors:  E M Shore; F H Gannon; F S Kaplan
Journal:  Rev Rhum Engl Ed       Date:  1997-06-30

3.  Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification.

Authors:  Devaveena Dey; Jana Bagarova; Sarah J Hatsell; Kelli A Armstrong; Lily Huang; Joerg Ermann; Ashley J Vonner; Yue Shen; Agustin H Mohedas; Arthur Lee; Elisabeth M W Eekhoff; Annelies van Schie; Marie B Demay; Charles Keller; Amy J Wagers; Aris N Economides; Paul B Yu
Journal:  Sci Transl Med       Date:  2016-11-23       Impact factor: 17.956

4.  Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.

Authors:  Michael P Whyte; Deborah Wenkert; Jennifer L Demertzis; Edward F DiCarlo; Erica Westenberg; Steven Mumm
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

5.  A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.

Authors:  Satoshi Ohte; Masashi Shin; Hiroki Sasanuma; Katsumi Yoneyama; Masumi Akita; Kenji Ikebuchi; Eijiro Jimi; Yuichi Maruki; Masaru Matsuoka; Akira Namba; Hiroshi Tomoda; Yasushi Okazaki; Akira Ohtake; Hiromi Oda; Ichiro Owan; Tetsuya Yoda; Hirokazu Furuya; Jyunji Kamizono; Hiroshi Kitoh; Yasuharu Nakashima; Takafumi Susami; Nobuhiko Haga; Tetsuo Komori; Takenobu Katagiri
Journal:  Biochem Biophys Res Commun       Date:  2011-03-04       Impact factor: 3.575

6.  A novel ACVR1 mutation detected by whole exome sequencing in a family with an unusual skeletal dysplasia.

Authors:  Maryam Rafati; Faezeh Mohamadhashem; Azadeh Hoseini; Fatemeh Hoseininasab; Saeed Reza Ghaffari
Journal:  Eur J Med Genet       Date:  2016-05-13       Impact factor: 2.708

7.  ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.

Authors:  Sarah J Hatsell; Vincent Idone; Dana M Alessi Wolken; Lily Huang; Hyon J Kim; Lili Wang; Xialing Wen; Kalyan C Nannuru; Johanna Jimenez; Liqin Xie; Nanditha Das; Genevieve Makhoul; Rostislav Chernomorsky; David D'Ambrosio; Richard A Corpina; Christopher J Schoenherr; Kieran Feeley; Paul B Yu; George D Yancopoulos; Andrew J Murphy; Aris N Economides
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

8.  The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment.

Authors:  Robert J Pignolo; Christopher Bedford-Gay; Moira Liljesthröm; Blythe P Durbin-Johnson; Eileen M Shore; David M Rocke; Frederick S Kaplan
Journal:  J Bone Miner Res       Date:  2015-11-14       Impact factor: 6.741

9.  Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.

Authors:  Apirat Chaikuad; Ivan Alfano; Georgina Kerr; Caroline E Sanvitale; Jan H Boergermann; James T Triffitt; Frank von Delft; Stefan Knapp; Petra Knaus; Alex N Bullock
Journal:  J Biol Chem       Date:  2012-09-12       Impact factor: 5.157

10.  Concurrent progress of reprogramming and gene correction to overcome therapeutic limitation of mutant ALK2-iPSC.

Authors:  Bu-Yeo Kim; SangKyun Jeong; Seo-Young Lee; So Min Lee; Eun Jeong Gweon; Hyunjun Ahn; Janghwan Kim; Sun-Ku Chung
Journal:  Exp Mol Med       Date:  2016-06-03       Impact factor: 8.718

View more
  10 in total

1.  Case Report: Unable to Jump Like a Kangaroo Due to Myositis Ossificans Circumscripta.

Authors:  Enrice I Huenerfauth; Viktor Molnár; Marco Rosati; Malgorzata Ciurkiewicz; Franz J Söbbeler; Oliver Harms; Robert Hildebrandt; Wolfgang Baumgärtner; Andrea Tipold; Holger A Volk; Jasmin Nessler
Journal:  Front Vet Sci       Date:  2022-07-04

Review 2.  Challenges in the treatment of fibrodysplasia ossificans progressiva.

Authors:  Kardelen Gencer-Atalay; Ekim Can Ozturk; Ilker Yagci; Pinar Ata; Kenan Delil; Zerrin Ozgen; Gulseren Akyuz
Journal:  Rheumatol Int       Date:  2018-10-20       Impact factor: 2.631

Review 3.  Left to themselves: Time to target chronic pain in childhood rare diseases.

Authors:  Christine B Sieberg; Alyssa Lebel; Erin Silliman; Scott Holmes; David Borsook; Igor Elman
Journal:  Neurosci Biobehav Rev       Date:  2021-03-24       Impact factor: 8.989

4.  Atypical Presentation of Fibrodysplasia Ossificans Progressiva: A Case Report and Review of Literature.

Authors:  Vivek Tiwari; Prateek Behera; Radha Sarawagi; Babu Mohammed Rafi; Saurabh Sahu; Hemanth Raj; Manish Rajpoot
Journal:  Cureus       Date:  2018-07-10

5.  Bilateral fibrodysplasia ossificans affecting the masticatory muscles and causing irreversible trismus in a domestic shorthair cat.

Authors:  Michel Guzu; Hugues A Gaillot; Marco Rosati; Alexandra Nicolier; Philippe R Hennet
Journal:  JFMS Open Rep       Date:  2019-04-03

Review 6.  Heterotopic Ossification: Clinical Features, Basic Researches, and Mechanical Stimulations.

Authors:  Yili Xu; Mei Huang; Wenzhen He; Chen He; Kaixuan Chen; Jing Hou; Min Huang; Yurui Jiao; Ran Liu; Nanyu Zou; Ling Liu; Changjun Li
Journal:  Front Cell Dev Biol       Date:  2022-01-25

Review 7.  Heterotopic ossification of tendon and ligament.

Authors:  Qiang Zhang; Dong Zhou; Haitao Wang; Jun Tan
Journal:  J Cell Mol Med       Date:  2020-04-15       Impact factor: 5.310

8.  Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome?

Authors:  Ruby Haviv; Veronica Moshe; Fabrizio De Benedetti; Giusi Prencipe; Noa Rabinowicz; Yosef Uziel
Journal:  Pediatr Rheumatol Online J       Date:  2019-12-21       Impact factor: 3.054

Review 9.  Fibrodysplasia ossificans progressiva: current concepts from bench to bedside.

Authors:  Arun-Kumar Kaliya-Perumal; Tom J Carney; Philip W Ingham
Journal:  Dis Model Mech       Date:  2020-09-21       Impact factor: 5.758

10.  A case of Fibrodysplasia Ossificans Progressiva associated with a novel variant of the ACVR1 gene.

Authors:  Serena Cappato; Rasa Traberg; Jolita Gintautiene; Federico Zara; Renata Bocciardi
Journal:  Mol Genet Genomic Med       Date:  2021-08-04       Impact factor: 2.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.